Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.
Xencor, Inc. develops engineered antibody therapeutics for cancer and autoimmune diseases using its XmAb technology platform and related antibody-engineering formats. News about XNCR commonly covers clinical and preclinical updates for XmAb drug candidates, including TL1A programs such as XmAb942 and XmAb412, T-cell engaging bispecific antibodies such as XmAb819 and XmAb541, and presentations of data at medical meetings.
Recurring company updates also include quarterly financial results, research-and-development priorities, collaboration and licensing activity, intellectual-property developments tied to Xtend Fc domain technology, and royalty matters involving partner-marketed medicines such as Ultomiris.
Xencor (NASDAQ: XNCR) has entered a clinical collaboration with MorphoSys AG and Incyte to evaluate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma.
This partnership aims to accelerate the clinical development of plamotamab, which has shown promise in treating non-Hodgkin lymphoma. The Phase 1/2 study will be conducted in North America, Europe, and Asia-Pacific.
Xencor, Inc. (NASDAQ:XNCR) has presented new data from its preclinical XmAb bispecific antibody and IL-12-Fc cytokine programs at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). This includes advancements in CD28 bispecific antibodies designed to co-stimulate T cells targeting tumor cells. The company showcased two selective TGFβ inhibitors and IL-12-Fc fusions, showing improved anti-tumor activity and potential benefits over existing therapies. Xencor continues to advance its innovative monoclonal antibody technology aimed at treating cancer and autoimmune diseases.
Xencor, Inc. (NASDAQ:XNCR) announced that data from its Phase 1 dose-escalation study of vibecotamab will be presented at the 2020 ASH Annual Meeting. Vibecotamab is a bispecific antibody targeting CD123 and CD3, developed for treating relapsed/refractory acute myeloid leukemia (AML). Initial results indicate that patients with low disease burden and specific T-cell signatures may respond better to treatment. Toxicities were primarily mild-to-moderate, with cytokine release syndrome observed in 58% of patients. The study continues to optimize dosing and prepare for future trials.
Xencor, Inc. (NASDAQ: XNCR) will announce its third quarter 2020 financial results on November 5, 2020, after market close. Management will host a webcast and conference call at 4:30 p.m. ET to discuss these results and provide a corporate update. Investors can access the call via phone or through the company’s website. Xencor focuses on developing engineered monoclonal antibodies targeting cancer and autoimmune diseases, with 18 candidates currently in clinical development leveraging its proprietary XmAb® technology.
Xencor, Inc. (NASDAQ:XNCR) has announced four poster presentations at the virtual 35th Annual Meeting of the Society for Immunotherapy of Cancer, scheduled for November 9-14, 2020. The presentations will showcase updated results from the Phase 1 study of XmAb®20717, a PD-1 x CTLA-4 bispecific antibody targeting advanced solid tumors. New data on three preclinical-stage programs will also be presented. The poster session will occur from November 11-14, with access to the materials available via Xencor's website.
Xencor, Inc. (NASDAQ:XNCR) announced initial data from its ongoing Phase 1 study of tidutamab (XmAb®18087), a bispecific antibody targeting neuroendocrine tumors (NETs). Presented at the NANETS 2020 symposium, the preliminary results indicate that tidutamab was well-tolerated, showing dose-dependent T-cell proliferation. The study involved 27 patients with various NETs, achieving a disease control rate of 43%. Xencor plans further studies in Merkel cell carcinoma and small cell lung cancer, emphasizing tidutamab's promising safety profile and potential efficacy in solid tumors.